Oxcarbazepine
1
Reactions 1425 - 27 Oct 2012 Oxcarbazepine Mild maculopapular eruptions: 14 case reports A study identified eight male and six female patients, aged 2–61 years, who developed mild maculopapular eruptions during treatment with oxcarbazepine for epilepsy [routes not stated]. The patients received oxcarbazepine, starting at 60–300 mg/day, titrated to 60–600 mg/day as monotherapy in 10 patients or, in 4 patients, as add-on treatment to existing antiepileptic drugs. After 1–35 days, they developed mild maculopapular eruptions; no patient required hospitalisation. Oxcarbazepine was discontinued and the patients received steroids or antihistamines. They recovered within 2 weeks. Author comment: "[T]he incidence of cADRs [cutaneous adverse drug reactions] induced by OXC [oxcarbazepine] was low in these new users of OXC following this slow titration. All of the reactions were mild [maculopapular eruption], and no severe reactions occurred. As a predictor of OXC-cADRs, history of allergy needs attentions before prescribing OXC." He N, et al. Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: Incidence, features, risk factors and relation to HLA-B alleles. Seizure: European Journal of Epilepsy 21: 614-618, No. 8, Oct 2012. Available from: URL: http://dx.doi.org/10.1016/j.seizure.2012.06.014 - China 803079066 1 Reactions 27 Oct 2012 No. 1425 0114-9954/10/1425-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
-
Upload
nguyenthuy -
Category
Documents
-
view
212 -
download
0
Transcript of Oxcarbazepine
Reactions 1425 - 27 Oct 2012
Oxcarbazepine
Mild maculopapular eruptions: 14 case reportsA study identified eight male and six female patients,
aged 2–61 years, who developed mild maculopapulareruptions during treatment with oxcarbazepine for epilepsy[routes not stated].
The patients received oxcarbazepine, starting at60–300 mg/day, titrated to 60–600 mg/day asmonotherapy in 10 patients or, in 4 patients, as add-ontreatment to existing antiepileptic drugs. After 1–35 days,they developed mild maculopapular eruptions; no patientrequired hospitalisation.
Oxcarbazepine was discontinued and the patientsreceived steroids or antihistamines. They recovered within2 weeks.
Author comment: "[T]he incidence of cADRs [cutaneousadverse drug reactions] induced by OXC [oxcarbazepine] waslow in these new users of OXC following this slow titration.All of the reactions were mild [maculopapular eruption], andno severe reactions occurred. As a predictor of OXC-cADRs,history of allergy needs attentions before prescribing OXC."He N, et al. Cutaneous reactions induced by oxcarbazepine in Southern HanChinese: Incidence, features, risk factors and relation to HLA-B alleles. Seizure:European Journal of Epilepsy 21: 614-618, No. 8, Oct 2012. Available from: URL:http://dx.doi.org/10.1016/j.seizure.2012.06.014 - China 803079066
1
Reactions 27 Oct 2012 No. 14250114-9954/10/1425-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
